OPRX · OptimizeRx Corp
$6.37
+0.03 (+0.47%)
At close · Jul 29
View the 10-Q filed May 13, 2026
Customer concentration
— top 5 customers 47% of revenue
5 customers — 47% of revenue (the year ended December 31, 2025)
“Our top five customers represented approximately 47% and 49% of our revenue for the years ended December 31, 2025 and 2024, respectively.”
3 customers — 10% of revenue (2025)
“In 2025 and 2024, we had three customers and two customers, respectively, that represented more than 10% of our revenues.”
5 customers — 49% of revenue (the year ended December 31, 2024)
“Our top five customers represented approximately 47% and 49% of our revenue for the years ended December 31, 2025 and 2024, respectively.”
2 customers — 10% of revenue (2024)
“In 2025 and 2024, we had three customers and two customers, respectively, that represented more than 10% of our revenues.”
Market Cap
$118.97M
Shares
18.77M
OptimizeRx Corp Earnings Call Transcripts
Every quarterly earnings call for OptimizeRx Corp (OPRX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼6.4%
$15.09M
−$3.47M
'22 Q3
22-11-08
▼3.2%
$19.65M
−$325,836
'22 Q4
23-03-08
▼5.3%
$13.00M
−$6.40M
'23 Q1
23-05-10
▼1.1%
$13.82M
−$4.16M
'23 Q2
23-08-14
▲8.3%
$16.33M
−$2.87M
'23 Q3
23-11-06
▲44.3%
$28.37M
−$4.14M
'23 Q4
24-03-11
▲51.4%
$19.69M
−$6.90M
'24 Q1
24-04-18
▲36.1%
$18.81M
−$4.01M
'24 Q2
24-08-08
▲30.5%
$21.31M
−$9.12M
'24 Q3
24-11-13
▲13.9%
$32.32M
−$78,000
'24 Q4
25-03-12
▲11.4%
$21.93M
−$2.20M
'25 Q1
25-05-12
▲55.2%
$29.20M
$1.53M
'25 Q2
25-08-07
▲22.3%
$26.07M
$779,000
'25 Q3
25-11-06
▼0.2%
$32.24M
$5.02M
'25 Q4
26-03-05
LATEST
▼9.5%
$19.84M
−$495,000
'26 Q1
26-05-12
Earnings call
FY26 · Q2
2026-08-12
OPRX 2nd Quarter 2026 Earnings Conference Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
William Blair & Company’s 46th Annual Growth Stock Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-12
OptimizeRx Corp Q1 FY2026 Earnings Call
Revenue
$19.84M
▼ 9.5% YoY Diluted EPS
$-0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
OptimizeRx Corp Q4 FY2025 Earnings Call
Positive tone
Q4 and FY2025 financial performance
Channel partners and competitive positioning
DAP (Dynamic Audience Activation Platform)
Revenue
$32.24M*
▼ 0.2% YoY Gross margin
74.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
OptimizeRx Corp Q3 FY2025 Earnings Call
Confident tone
Rule of 40 and Profitability
Omnichannel Platform and Technology
Revenue Growth and Beat
Revenue
$26.07M
▲ 22.3% YoY Diluted EPS
$0.04
Gross margin
67.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
OptimizeRx Corp Q2 FY2025 Earnings Call
Confident tone
Revenue growth and financial outperformance
Debt paydown and balance sheet
Omnichannel platform and competitive positioning
Revenue
$29.20M
▲ 55.2% YoY Diluted EPS
$0.08
Gross margin
63.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
OptimizeRx Corp Q1 FY2025 Earnings Call
Confident tone
Gross margin and product mix
Revenue growth and beat
Pipeline and customer KPIs
Revenue
$21.93M
▲ 11.4% YoY Diluted EPS
$-0.12
Gross margin
60.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-12
OptimizeRx Corp Q4 FY2024 Earnings Call
Confident tone
2025 guidance and growth outlook
Rule of 40 and recurring revenue model
HCP and DTC integration / competitive positioning
Revenue
$32.32M*
▲ 13.9% YoY Gross margin
68.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-13
OptimizeRx Corp Q3 FY2024 Earnings Call
Positive tone
DTC micro-neighborhood / self-service pivot
Q3 revenue shortfall
DAAP AI-driven omnichannel platform
Revenue
$21.31M
▲ 30.5% YoY Diluted EPS
$-0.50
Gross margin
63.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
OptimizeRx Corp Q2 FY2024 Earnings Call
Positive tone
DAAP conversion and momentum
Medicx Health acquisition integration
Full-year revenue guidance and visibility
Revenue
$18.81M
▲ 36.1% YoY Diluted EPS
$-0.22
Gross margin
62.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-18
OptimizeRx Corp Q1 FY2024 Earnings Call
Confident tone
DAAP (Dynamic Audience Activation Platform)
Cross-sell and pipeline expansion
Financial performance (gross margin, expenses, net loss)
Revenue
$19.69M
▲ 51.4% YoY Diluted EPS
$-0.38
Gross margin
62.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-11
OptimizeRx Corp Q4 FY2023 Earnings Call
Confident tone
DAAP Platform Growth
Medicx Health Acquisition & Integration
Cost Optimization
Revenue
$28.37M*
▲ 44.3% YoY Gross margin
62.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
OptimizeRx Corp Q3 FY2023 Earnings Call
Revenue
$16.33M
▲ 8.3% YoY Diluted EPS
$-0.17
Gross margin
60.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
OptimizeRx Corp Q2 FY2023 Earnings Call
Revenue
$13.82M
▼ 1.1% YoY Diluted EPS
$-0.24
Gross margin
56.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
OptimizeRx Corp Q1 FY2023 Earnings Call
Revenue
$13.00M
▼ 5.3% YoY Diluted EPS
$-0.37
Gross margin
57.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-08
OptimizeRx Corp Q4 FY2022 Earnings Call
Revenue
$19.65M*
▼ 3.2% YoY Gross margin
63.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
OptimizeRx Corp Q3 FY2022 Earnings Call
Revenue
$15.09M
▼ 6.4% YoY Diluted EPS
$-0.19
Gross margin
62.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
OptimizeRx Corp Q2 FY2022 Earnings Call
Revenue
$13.98M
▲ 2.6% YoY Diluted EPS
$-0.21
▼ 1150% YoY Gross margin
64.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
OptimizeRx Corp Q1 FY2022 Earnings Call
Revenue
$13.73M
▲ 22.3% YoY Diluted EPS
$-0.21
Gross margin
59.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-15
OptimizeRx Corp Q4 FY2021 Earnings Call
Revenue
$20.31M*
▲ 23.7% YoY Gross margin
61.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
OptimizeRx Corp Q3 FY2021 Earnings Call
Revenue
$16.12M
▲ 53.3% YoY Diluted EPS
$0.00
Gross margin
56.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-27
OptimizeRx Corp Q2 FY2021 Earnings Call
Revenue
$13.63M
▲ 55.1% YoY Diluted EPS
$0.02
Gross margin
59.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-28
OptimizeRx Corp Q1 FY2021 Earnings Call
Revenue
$11.23M
▲ 48.1% YoY Diluted EPS
$-0.04
Gross margin
54.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
OptimizeRx Corp Q4 FY2020 Earnings Call
Revenue
$16.43M*
▲ 122.6% YoY Gross margin
52.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-13
OptimizeRx Corp Q3 FY2020 Earnings Call
Revenue
$10.52M
▲ 110.3% YoY Diluted EPS
$-0.02
Gross margin
57.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-23
OptimizeRx Corp Q2 FY2020 Earnings Call
Revenue
$8.78M
▲ 25.4% YoY Diluted EPS
$-0.07
▼ 333.3% YoY Gross margin
58.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-16
OptimizeRx Corp Q1 FY2020 Earnings Call
Revenue
$7.58M
▲ 45.6% YoY Diluted EPS
$-0.15
Gross margin
57.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-28
OptimizeRx Corp Q4 FY2019 Earnings Call
Revenue
$7.38M*
▲ 12.2% YoY Gross margin
60.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
1448431
CUSIP
68401U204
13F (30d)
19 filings
19 filers
Visit website
Investor relations